ORF3B_SARS2
ID ORF3B_SARS2 Reviewed; 22 AA.
AC P0DTF1;
DT 10-FEB-2021, integrated into UniProtKB/Swiss-Prot.
DT 10-FEB-2021, sequence version 1.
DT 03-AUG-2022, entry version 6.
DE RecName: Full=Putative ORF3b protein {ECO:0000305|PubMed:32854725};
DE Short=ORF3b;
OS Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC Betacoronavirus; Sarbecovirus.
OX NCBI_TaxID=2697049;
OH NCBI_TaxID=9606; Homo sapiens (Human).
RN [1]
RP NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT "A new coronavirus associated with human respiratory disease in China.";
RL Nature 579:265-269(2020).
RN [2]
RP REVIEW.
RX PubMed=32854725; DOI=10.1186/s12985-020-01402-1;
RA Michel C.J., Mayer C., Poch O., Thompson J.D.;
RT "Characterization of accessory genes in coronavirus genomes.";
RL Virol. J. 17:131-131(2020).
RN [3]
RP MISCELLANEOUS.
RX PubMed=32807944; DOI=10.1038/s41590-020-0773-7;
RA Hachim A., Kavian N., Cohen C.A., Chin A.W.H., Chu D.K.W., Mok C.K.P.,
RA Tsang O.T.Y., Yeung Y.C., Perera R.A.P.M., Poon L.L.M., Peiris J.S.M.,
RA Valkenburg S.A.;
RT "ORF8 and ORF3b antibodies are accurate serological markers of early and
RT late SARS-CoV-2 infection.";
RL Nat. Immunol. 21:1293-1301(2020).
RN [4]
RP FUNCTION.
RX PubMed=32941788; DOI=10.1016/j.celrep.2020.108185;
RG USFQ-COVID19 Consortium;
RA Konno Y., Kimura I., Uriu K., Fukushi M., Irie T., Koyanagi Y., Sauter D.,
RA Gifford R.J., Nakagawa S., Sato K.;
RT "SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is
RT Increased by a Naturally Occurring Elongation Variant.";
RL Cell Rep. 32:108185-108185(2020).
RN [5]
RP GENOME REANNOTATION.
RX PubMed=33976134; DOI=10.1038/s41467-021-22905-7;
RA Jungreis I., Sealfon R., Kellis M.;
RT "SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44
RT Sarbecovirus genomes.";
RL Nat. Commun. 12:2642-2642(2021).
CC -!- FUNCTION: Acts as an interferon antagonist when expressed ex vivo.
CC {ECO:0000269|PubMed:32941788}.
CC -!- INTERACTION:
CC P0DTF1; P52954: LBX1; Xeno; NbExp=3; IntAct=EBI-26953451, EBI-20141748;
CC P0DTF1; Q9GZY8: MFF; Xeno; NbExp=3; IntAct=EBI-26953451, EBI-11420856;
CC -!- MISCELLANEOUS: SARS-CoV-2 ORF3b is homologous to SARS-CoV ORF3b,
CC although the proposed protein is much shorter due to the presence of
CC premature stop codons (Probable). Elicits strong specific antibody
CC response (PubMed:32807944). {ECO:0000269|PubMed:32807944,
CC ECO:0000305|PubMed:32854725}.
CC -!- CAUTION: Product of a dubious CDS prediction.
CC {ECO:0000303|PubMed:33976134}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; MN908947; -; NOT_ANNOTATED_CDS; Genomic_RNA.
DR IntAct; P0DTF1; 6.
DR Proteomes; UP000464024; Genome.
PE 5: Uncertain;
KW Interferon antiviral system evasion; Reference proteome.
FT CHAIN 1..22
FT /note="Putative ORF3b protein"
FT /id="PRO_0000452089"
SQ SEQUENCE 22 AA; 2457 MW; 53D80549C8F78A22 CRC64;
MMPTIFFAGI LIVTTIVYLT IV